Literature DB >> 2347037

The effect of route of administration and fractionation of dose on the metabolism of ifosfamide.

M J Lind1, H L Roberts, N Thatcher, J R Idle.   

Abstract

The measurement of urinary ifosfamide, isophosphoramide mustard, dechloroethyl ifosfamide and carboxyifosfamide using high-performance thin-layer chromatography with photographic densitometry (TLC-PD) is described. This technique was also used to demonstrate the large inter-individual variation in the ifosfamide metabolic profile of patients receiving the drug as single-agent therapy for non-small-cell lung cancer. In addition, oral administration was shown to result in higher levels of these metabolites in the urine. Fractionation of the ifosfamide dose over several days resulted in increasing levels of metabolites in the urine, consistent with auto-induction of ifosfamide metabolism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2347037     DOI: 10.1007/bf02897254

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Combined thin-layer chromatography-photography-densitometry for the quantitation of cyclophosphamide and its four principal urinary metabolites.

Authors:  A H Hadidi; J R Idle
Journal:  J Chromatogr       Date:  1988-05-13

2.  Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.

Authors:  T A Connors; P J Cox; P B Farmer; A B Foster; M Jarman
Journal:  Biochem Pharmacol       Date:  1974-01-01       Impact factor: 5.858

3.  Toxicity profile of chloroacetaldehyde.

Authors:  W H Lawrence; E O Dillingham; J E Turner; J Autian
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

4.  Urinary metabolites of the antitumor agent cyclophosphamide.

Authors:  R F Struck; M C Kirk; L B Mellett; S el Dareer; D L Hill
Journal:  Mol Pharmacol       Date:  1971-09       Impact factor: 4.436

5.  Dechloroethylation of ifosfamide and neurotoxicity.

Authors:  M P Goren; R K Wright; C B Pratt; F E Pell
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

6.  Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia.

Authors:  J Hilton
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

7.  The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents.

Authors:  L F Chasseaud
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

8.  Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

9.  Studies on the human pharmacokinetics of isophosphamide (NSC-109724).

Authors:  L M Allen; P J Creaven; R L Nelson
Journal:  Cancer Treat Rep       Date:  1976-04

10.  Bioavailability of ifosfamide in patients with bronchial carcinoma.

Authors:  T Cerny; J M Margison; N Thatcher; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more
  19 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 3.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

4.  The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.

Authors:  A V Boddy; M Cole; A D Pearson; J R Idle
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Authors:  J Boos; U Welslau; J Ritter; G Blaschke; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.

Authors:  T Cerny; G Martinelli; A Goldhirsch; F Terrier; R Joss; M F Fey; K W Brunner; A Küpfer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 7.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

8.  Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.

Authors:  T Cerny; A Graf; P Rohner; T Zeugin; K W Brunner; A Küpfer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 9.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

10.  Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.

Authors:  V Gilard; M C Malet-Martino; M de Forni; U Niemeyer; J C Ader; R Martino
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.